Reminyl 8 Mg 28 extended release caps

1. What is REMINYL and what is it used for?

Each REMINYL 8 mg extended-release capsule contains 10.25 mg of galantamine hydrobromide, equivalent to 8 mg of galantamine, as the active ingredient.

Capsules are produced in an extended-release form. This means a slow release of the drug from the capsule.

REMINYL belongs to a group of medicines called antidementia medicines.

It is presented in packages containing 28 capsules.

REMINYL is used in adults to treat symptoms of mild to moderate Alzheimer’s disease, a type of dementia that changes brain function. Alzheimer’s disease leads to increased memory loss, confusion, and behavioral changes that make it increasingly difficult to perform normal daily activities. These effects are thought to be due to a lack of “acetylcholine”, a substance responsible for transmitting messages between brain cells. REMINYL increases the amount of acetylcholine in the brain and treats the symptoms of the disease.

2. How to use REMINYL?

Always take this medicine exactly as your doctor or pharmacist has told you. Consult your doctor or pharmacist if you are unsure about anything.

If you are currently taking REMINYL oral solution and your doctor has told you to switch to REMINYL extended-release capsules, carefully read the instructions under the heading “Switching from REMINYL oral solution to REMINYL extended-release capsules” in this section.
Instructions for proper use and dose/frequency of administration

You will start your REMINYL treatment with a low dose. The usual dose is 8 mg taken once a day. Your doctor may gradually increase your dose at intervals of 4 weeks or longer until you reach the most suitable dose for you. The maximum dose is 24 mg taken once a day.

Your doctor will explain which dose to start with and when to increase the dose. If you are not sure what to do or if you think the effect of REMINYL is too strong or too weak, talk to your doctor or pharmacist.

Switching from REMINYL oral solution to REMINYL extended-release capsules

If you are currently taking REMINYL oral solution, your doctor may decide that you should switch to REMINYL extended-release capsule therapy. If this applies to you:

Take the last dose of REMINYL oral solution in the evening.

Take the first dose of REMINYL extended-release capsules the next morning.

Do not take more than one capsule in a day. Do not take REMINYL oral solution while taking REMINYL capsules.
Application route and method

It is taken orally.

Take your REMINYL capsule once a day in the morning with water or other liquids. Try to take your REMINYL dose with food.

Swallow the capsules whole, without chewing or crushing them. Drink plenty of fluids to avoid dehydration during your treatment with REMINYL.
different age groups
Use in children

Use in the elderly

Use in the elderly:

There is no special requirement.
Special use cases
Kidney failure

3. What are the possible side effects?

Like all medicines, there may be side effects in people who are sensitive to the substances contained in REMINYL.

Beware of serious side effects.

If any of the following occur, stop using REMINYL and IMMEDIATELY inform your doctor or go to the nearest hospital emergency department:

allergic reaction

skin reactions (including:)

– Blisters and skin eruptions, especially around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome).

– Red rashes spreading to the whole body, sometimes accompanied by fever (acute generalized exanthematous pustulosis).

– Redness causing blisters that develop with spots that look like small foci.

– If you have trouble breathing or wheezing, or experience swelling of your face, tongue and throat, these may be signs of a serious allergy called anaphylaxis.

These skin reactions are rare in people taking REMINYL (may affect up to 1 in 1000 people).

Heart problems, including changes in heartbeat (such as slowed beat rate, extra beats), Heart problems may be manifested by an abnormal recording on an electrocardiogram (ECG) and may be common in people taking REMINYL (may affect up to 1 in 10 people).